CEBPA and acute myeloid leukemia: The 2008 revision extended to seven the number of AML cytogenetic subtypes and recognized, for the first time, gene mutations as entity-defining lesions (provisional AML with mutated NPM1 and AML with mutated CEBPA) [30].